POM
PomDoctor Ltd.
NASDAQ · Healthcare · Medical - Pharmaceuticals · CN
$1.99
+10.56%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 345.0M | 399.9M | 342.6M | 304.9M | 245.2M |
| Cost of Revenue | 304.7M | 347.6M | 294.9M | 266.1M | 190.4M |
| Gross Profit | 40.3M | 52.3M | 47.7M | 38.7M | 54.9M |
| Operating Expenses | |||||
| R&D Expense | 80.1M | 12.9M | 3.0M | 3.4M | 3.6M |
| SG&A Expense | 269.6M | 155.9M | 68.2M | 56.0M | 54.9M |
| General & Admin Expense | 124.7M | 59.7M | 11.9M | 12.3M | 7.4M |
| Selling & Marketing Expense | 144.9M | 96.2M | 56.4M | 43.7M | 47.5M |
| Other Expenses | (53.4M) | (152.6K) | 2.2M | 1.6M | — |
| Total Operating Expenses | 296.2M | 168.7M | 73.5M | 61.0M | 58.5M |
| Cost and Expenses | 600.9M | 516.3M | 368.3M | 327.1M | 248.8M |
| Operating Income (EBIT) | (255.9M) | (116.4M) | (25.8M) | (22.2M) | (3.6M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 895.7K | 12.9M | 13.0M | 13.8M | 16.0M |
| Net Interest Income | (10.4M) | (12.9M) | (13.0M) | (13.8M) | (16.0M) |
| Other Non-Op Income/Expense | (38.3M) | (14.6M) | (11.6M) | (14.7M) | (16.2M) |
| Non-Operating Income (excl Interest) | (295.5K) | 1.7M | (1.4M) | 851.4K | 214.4K |
| EBT (Pre-Tax Income) | (294.2M) | (130.9M) | (37.4M) | (36.9M) | (19.8M) |
| Income Tax Expense | 43.8K | 375.00 | — | — | — |
| Bottom Line | |||||
| Net Income | (288.8M) | (212.6M) | (143.4M) | (145.4M) | (125.5M) |
| Earnings from Cont. Ops | (294.2M) | (130.9M) | (37.4M) | (36.9M) | (19.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (288.8M) | (212.6M) | (143.4M) | (145.4M) | (125.5M) |
| Per Share | |||||
| Basic EPS | ($61.98) | ($65.88) | ($68.16) | ($69.12) | ($93.15) |
| Diluted EPS | ($61.98) | ($65.88) | ($68.16) | ($69.12) | ($93.15) |
| Revenue Per Share | $44.65 | $123.94 | $162.87 | $144.93 | $182.00 |
| Shares | |||||
| Basic Shares Outstanding | 7.7M | 3.2M | 2.1M | 2.1M | 1.3M |
| Diluted Shares Outstanding | 7.7M | 3.2M | 2.1M | 2.1M | 1.3M |
| Profitability Metrics | |||||
| EBITDA | (255.5M) | (117.9M) | (24.3M) | (23.0M) | (3.8M) |
| D&A | 152.8K | 149.3K | 134.5K | 112.1K | — |
| EBIT | (255.6M) | (118.0M) | (24.4M) | (23.1M) | (3.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026